By Rajasri Chandra, MS, MBA
This article explores evolving paradigms in diabetes diagnosis and classification aligned with the 2025 Standards of Care from the American Diabetes Association. It reviews pathophysiologic distinctions among type 1, type 2, monogenic, and gestational diabetes, emphasizing accurate classification to reduce misdiagnosis and guide personalized therapy. The article details current laboratory screening and confirmatory criteria, including A1C, fasting plasma glucose, oral glucose tolerance testing, C-peptide, and islet autoantibody assessment. It also examines emerging applications of artificial intelligence in risk prediction, glucose monitoring, and individualized management strategies, highlighting opportunities to improve outcomes, enhance efficiency, and address growing global diabetes prevalence.
LEARNING OBJECTIVES
Upon completion of this article, the reader will be able to:
- Describe the pathophysiologies in the classifications of diabetes.
- Discuss the laboratory tests and their results in the diagnosis of the classifications of diabetes.
- Differentiate confirmatory data of laboratory testing in the confirmation of diabetes.
- Discuss AI strategies for the prediction and management of diabetes.
Rajasri Chandra, MS, MBA is a global marketing leader with expertise in managing upstream, downstream, strategic, tactical, traditional, and digital marketing in biotech, in vitro diagnostics, life sciences, and pharmaceutical industries. Raj is an orchestrator of go-to-market strategies driving complete product life cycle from ideation to commercialization.
Course Includes
- 1 Lesson
- 1 Test
- Course Certificate
Medical Laboratory Observer (MLO) is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program.
Level of Instruction: Intermediate
Passing scores of 70 percent or higher are eligible for 1 contact hour of P.A.C.E. credit. This test is no longer valid for CEs after July 2026.
